Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

Published:2015-07 Issue:1 Volume:136 Page:116-124.e7
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Krueger James G.,Ferris Laura K.,Menter Alan,Wagner Frank,White Alexander,Visvanathan Sudha,Lalovic Bojan,Aslanyan Stella,Wang Elaine E.L.,Hall David,Solinger Alan,Padula Steven,Scholl Paul

Funder

Boehringer Ingelheim

Pfizer

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference28 articles.

1. Immunology of psoriasis;Lowes;Annu Rev Immunol,2014

2. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction;Stern;J Investig Dermatol Symp Proc,2004

3. Psoriasis vulgaris and psoriasis pustulosa—epidemiology, quality of life, comorbidities and treatment;Pfohler;Curr Rheumatol Rev,2013